Sign in
Taking people in United StatesPhase 1

Tests HM17321 safety in healthy and obese adults

Tests a new drug, HM17321, in healthy and obese adults to check safety.

Key facts

Who runs it
Hanmi Pharmaceutical Company Limited
Where
Cincinnati, United StatesSee the site
Trial code
Registry title
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
Status
Recruiting
Phase
Phase 1
People taking part
90 people, planned
Started
6 Nov 2025
Expected to end
Mar 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HM17321
  • Placebo of HM17321
Record updated
4 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-65 who are either healthy (Part A) or healthy and obese (Part B), to test the safety of the drug HM17321.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Part A: healthy people with BMI from 20 to 27 kg/m². Part B: obese people with BMI from 30 to 45 kg/m².
Earlier treatment
Stable body weight (less than 5% change) in the past 3 months. In Part B, no weight control treatments or blood pressure medicines in the 3 months before screening.

Main reasons for not taking part

  • Past bariatric (weight loss) surgery
  • Positive test for hepatitis B, hepatitis C or HIV
  • Pregnant, planning pregnancy or breastfeeding
  • Diabetes (Part B)
  • Clinically significant heart, liver, pancreas or kidney problems

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Adults aged 18-65 years
  • Part A: Healthy participants with BMI ≥20 kg/m² and ≤27 kg/m² at screening
  • Part B: Healthy obese participants with BMI ≥30 kg/m² and ≤45 kg/m² at screening
  • Stable body weight (<5% change) in the past 3 months
  • Able and willing to provide written informed consent
  • Male participants must use contraception or remain abstinent from women of childbearing potential
  • Female participants must not be pregnant or breastfeeding and use highly effective contraception if of childbearing potential

Who cannot take part

  • Use of any investigational product within 30 days or 5 half-lives (whichever is longer) prior to screening
  • History of any bariatric procedure
  • Uncontrolled thyroid disease (TSH >6.0 or <0.4 mIU/L)
  • Positive test for hepatitis B, hepatitis C, or HIV at screening
  • History of drug or alcohol abuse within defined timeframes (e.g., alcohol >14 standard units/week in past year, or positive drug screen)
  • Abnormal liver function or clinically significant liver disease; Part A: ALT or AST ≥ ULN, or total bilirubin ≥ ULN; Part B: ALT or AST >2× ULN, or total bilirubin >1.5× ULN
  • Abnormal pancreatic function; Part A: amylase or lipase ≥ ULN; Part B: amylase or lipase >3× ULN
  • Clinically significant cardiovascular disorders (e.g., myocardial infarction, congestive heart failure, long QT syndrome)
  • Abnormal renal function (eGFR <60 mL/min/1.73 m²)
  • Additional Exclusion Criteria for Part B; HbA1c ≥6.5% or a history of diabetes mellitus (type 1 or type 2); Obesity induced by other endocrine disorders (e.g., Cushing syndrome); Use of weight control treatments (e.g., GLP-1 receptor agonists or other anti-obesity medications) and antihypertensive medications within 3 months prior to screening; Use of any lipid-lowering medications, unless on a stable dose for at least 3 months prior to screening
  • Women who are pregnant, planning to become pregnant, or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Medpace Clinical Pharmacology UnitCincinnati, United StatesContact: Leela Vrishabhendra (principal investigator)Taking people

About the trial

What the trial wants to find out

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.

The 2 groups in the trial

  • HM17321Treatment being tested
  • PlaceboPlacebo, for comparison

    Treatment: Placebo of HM17321

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM17321 in Healthy and Obese Participants
Plain-language title
Tests HM17321 safety in healthy and obese adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07219589, who can take part
Record updated
4 May 2026